Clinical Study

A Phase 2 Randomized Study Of Efatutazone, An Oral Ppar Agonist, In Combination With Paclitaxel Versus Paclitaxel In Patients With Advanced Anaplastic Thyroid Cancer

Posted Date: Aug 16, 2017

  • Investigator: Muhammad Riaz
  • Specialties: Hematology/Oncology, Oncology, Cancer
  • Type of Study: Drug

The purpose of this study is to compare any good and bad effects of using efatutazone along with the usual chemotherapy to using the usual chemotherapy alone.

Criteria:

To Be Eligible For This Study, Patients Must Have Anaplastic Thyroid Cancer Which Cannot Be Removed With Surgery Or Has Spread To Other Areas Of The Body.

Keywords:

A091305, Thyroid Cancer, Cancer, Advanced Anaplastic Thyroid Cancer, Head & Neck

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com